Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Approvals Action
MS drug faces first generic

Posted 16 November 2020 

The first copy of Teva's PBS-listed Copaxone has been registered in Australia along with Celltrion's latest biosimilar of infliximab, threatening other products on the market.

Juno Pharmaceuticals' Glatira and Multiros mark the first generic brands for multiple sclerosis injection Copaxone, which has been available since 2003.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
Picking the path out of Covid
Now is not the time for leaders to play it safe
Special Report
Aust Covid Vaccine Tracker
UPDATE: Gilead hits back at WHO over remdesivir
Approvals Action
Trio of new drugs on ARTG
Roche, Seqirus, Clinuvel enlarge local portfolios